<DOC>
	<DOCNO>NCT01171898</DOCNO>
	<brief_summary>The purpose study assess safety activity ARN-509 men advance castration resistant prostate cancer . Patients first enrol Phase 1 study identify tolerable dose Phase 2 portion study . In Phase 2 , 3 different cohort patient enrol evaluate safety activity ARN-509 .</brief_summary>
	<brief_title>Safety , Pharmacokinetic Proof-of-Concept Study ARN-509 Castration-Resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>NONMETASTATIC CRPC Inclusion Criteria 1 . Histologically cytologically proven prostate cancer high risk development metastasis , define either PSA value &gt; =8 ng/mL within last 3 month PSA Doubling Time &lt; =10 month 2 . Ongoing androgen depletion therapy Gonadotropin Releasing Hormone ( GnRH ) analogue inhibitor , orchiectomy ( i.e. , surgical medical castration ) 3 . Castrate level serum testosterone less equal 50 ng/dL 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 5 . A life expectancy least 3 month Exclusion Criteria 1 . Distant metastasis , include CNS vertebral meningeal involvement 2 . Prior treatment MDV3100 3 . Prior treatment abiraterone 4 . Prior treatment ketoconazole 5 . Concurrent treatment medication know seizure potential 6 . Concurrent treatment corticosteroid . If already steroid , patient allow enroll study need taper soon possible . 7 . QTc &gt; 450 msec 8 . History seizure condition may predispose seizure 9 . Evidence severe uncontrolled systemic disease HIV infection METASTATIC CRPC , TREATMENTNAIVE Inclusion Criteria 1 . Histologically cytologically proven prostate cancer progressive disease base either PSA radiographic progression 2 . Ongoing androgen depletion therapy Gonadotropin Releasing Hormone ( GnRH ) analogue inhibitor , orchiectomy ( i.e. , surgical medical castration ) 3 . Castrate level serum testosterone less equal 50 ng/dL 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 5 . A life expectancy least 3 month Exclusion Criteria 1 . History , current metastasis brain untreated spinal cord compression 2 . Prior treatment MDV3100 3 . Prior treatment abiraterone 4 . Prior treatment ketoconazole 5 . Concurrent treatment medication know seizure potential 6 . Concurrent treatment corticosteroid . If already steroid , patient allow enroll study need taper soon possible . 7 . QTc &gt; 450 msec 8 . History seizure condition may predispose seizure 9 . Evidence severe uncontrolled systemic disease HIV infection METASTATIC CRPC , CHEMOTHERAPYNAIVE , POSTABIRATERONE Inclusion Criteria 1 . Histologically cytologically proven prostate cancer progressive disease base either PSA radiographic progression 2 . Ongoing androgen depletion therapy Gonadotropin Releasing Hormone ( GnRH ) analogue inhibitor , orchiectomy ( i.e. , surgical medical castration ) 3 . Castrate level serum testosterone less equal 50 ng/dL 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 5 . A life expectancy least 3 month 6 . Patients must receive minimum 6 month abiraterone treatment prior disease progression Exclusion Criteria 1 . History , current metastasis brain untreated spinal cord compression 2 . Prior treatment MDV3100 3 . Prior treatment ketoconazole 4 . Concurrent treatment medication know seizure potential 5 . Concurrent treatment corticosteroid . If already steroid , patient allow enroll study need taper soon possible . 6 . QTc &gt; 450 msec 7 . History seizure condition may predispose seizure 8 . Evidence severe uncontrolled systemic disease HIV infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-Metastatic</keyword>
	<keyword>Rising PSA</keyword>
	<keyword>Castration-Resistant</keyword>
	<keyword>Treatment-Naive</keyword>
	<keyword>Post-abiraterone</keyword>
</DOC>